Maratón de Detroit

Two participants in the Detroit Marathon will be adding onto their marathon experiences by fundraising for AFTD’s mission while they train and run in the race. Glenna Sikdar Creek is running in honor of her mother Carla who is currently living with FTD and Kelly Collins is also running in honor of her mother who…

Lee mas

Media Maratón Life Time de Chicago

Ana Gaither and some members of her family will be running in the 2025 Life Time Chicago Half Marathon this fall in memory of Ana’s aunt Erin Lynch- McNulty who was diagnosed with FTD and recently passed away.

Lee mas

Jersey Freeze Ice Cream Party

AFTD Advocacy Coordinator Lauren Pelaia is hosting a sweet fundraiser at Jersey Freeze on July 10th. A portion of the sales that day from the ice cream parlor and restaurant will be donated to AFTD’s mission in memory of Lauren’s mother. Make sure to mention the event when you order to get a portion of…

Lee mas

Estimada línea de ayuda: Subvenciones Comstock

Graphic Text: Dear HelpLine - Comstock Grants | Background: A jar of assorted change overflows onto a table

Dear HelpLine, We recently joined an FTD support group, which has been so helpful. The support group volunteer told us about AFTD’s Comstock Grants. Can you help us learn more? Living with FTD brings significant changes for both persons diagnosed and their care partners. As symptoms emerge — behavioral changes, language challenges, cognitive shifts —…

Lee mas

Promoviendo la esperanza; AFTD asiste a la Conferencia Global Tau

Text: Advancing Hope - AFTD Attends the Tau Global Conference | Background: A photo of AFTD staff members Drs Nicole Bjorklund and Katherine Still at the 2025 Taul Global Conference

In late April, AFTD Research team members attended a premier conference focused exclusively on research into tau, a protein which is aggregated in Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), MAPT Frontotemporal Degeneration, Alzheimer’s Disease, and other neurodegenerative disorders. This conference was co-hosted by the Alzheimer’s Association, CurePSP, and the Rainwater Charitable Foundation. It brought…

Lee mas

Se encontró patología cerebral compatible con DFT en aproximadamente 35% de los casos de enfermedad de la neurona motora en un estudio reciente

Graphic Text: Brain Pathology Consistent with FTD Found in Roughly 35% of Motor Neuron Disease Cases in Recent Study

According to a recent study published in the research journal Brain, brain pathology consistent with FTD was detected in roughly 35% of the participants with motor neuron disease, which includes diseases like ALS. Abnormal protein clumps were detected in 90% of the samples studied, with participants classified as having both FTD and motor neuron disease…

Lee mas

La prometedora terapia génica para la DFT de AviadoBio aparece en el periódico británico The Guardian.

In London’s Docklands, British biotech company AviadoBio is developing a promising gene therapy to treat FTD. The Guardian wrote about the company’s progress on June 13. AviadoBio’s lead therapy, AVB-101, targets the specific genetic form FTD-GRN, caused by mutations that create a deficiency in progranulin, a protein essential for healthy brain cells. The treatment represents…

Lee mas

Resumen científico de la DFT: Contribuya al avance científico uniéndose al Registro actualizado de trastornos de la DFT

Banner Text: Help Advance Science by Joining the Updated FTD Disorders Registry

It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than ever. Trials targeting sporadic FTD are also emerging, such as an ongoing trial on semantic variant primary progressive aphasia (svPPA) and an upcoming platform trial…

Lee mas

Investigación destacada sobre DFT: un nuevo portal para investigadores y otras actualizaciones del Registro de Trastornos de DFT

Banner: FTD Research Spotlight: A New Researcher Portal and Other Updates from the FTD Disorders Registry

It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than ever. Trials targeting sporadic FTD are also emerging, such as an ongoing trial on semantic variant primary progressive aphasia (svPPA) and an upcoming platform trial…

Lee mas